Variables | Last status | CHR (95% CI) | AHR (95% CI) | p value | |
---|---|---|---|---|---|
Event | Censored | ||||
Sex | |||||
Male | 40 | 162 | 1.0 | 1.0 | |
Female | 44 | 238 | 0.81 (0.53,1.23) | 0.88 (0.54, 1.42) | 0.58 |
ART regimen | |||||
1a | 8 | 56 | 1.0 | 1.0 | |
1b | 13 | 48 | 1.6 (0.7, 3.9) | 1.6 (0.6, 3.9) | 0.37 |
1c | 14 | 66 | 1.99 (0.83, 4.8) | 2.79 (1.07, 7.23) | 0.32 |
1d | 9 | 31 | 2.4 (0.94, 6.4) | 3.14 (1.13, 8.08) | 0.19 |
1e | 40 | 199 | 6.7 (3.14, 14.7) | 9.3 (3.75 , 23.8) | 0.10 |
History of ART adherence | |||||
Poor | 23 | 77 | 1.0 | 1.0 | |
Good | 61 | 323 | 0.5(0.3, 0.8) | 1.2(0.3, 0.9) | 0.20 |
WHO clinical stage | |||||
Stage I | 11 | 106 | 1.0 | 1.0 | |
Stage II | 8 | 66 | 0.7 (0.29, 0.1.81) | 1.09 (0.42, 2.85) | 0.45 |
Stage III | 48 | 172 | 1.44 (0.75, 2.78) | 1.73 (0.87, 3.46) | 0.20 |
Stage IV | 17 | 56 | 1.8 (0.83, 3.8) | 2.75 (1.23, 6.16) | 0.01 |
Residence | |||||
Urban | 55 | 217 | 1.0 | 1.0 | |
Rural | 29 | 183 | 0.5 (0.33, 0.8) | 0.6 (0.37, 0.99) | 0.046 |
Phone | |||||
Yes | 68 | 352 | 1.0 | 1.0 | |
No | 16 | 48 | 1.5 (0.87, 2.6) | 1.9 (1.14, 3.4) | 0.04 |
Age categories | |||||
15–24 | 13 | 40 | 1.0 | 1.0 | |
25–34 | 41 | 169 | 0.44 (.22, 0.88) | 0.67 (0.35, 1.29) | 0.20 |
35–44 | 22 | 127 | 0.4 (0.22, 0.86) | 0.32 (0.15, 0.67) | 0.20 |
≥ 45 | 8 | 64 | 0.4 (0.17, 0.99) | 0.33 (0.13, 0.83) | 0.19 |
Baseline CD4 Count | |||||
≤ 50 | 11 | 46 | 1.0 | 1.0 | |
50–150 | 28 | 125 | 0.68 (0.34, 1.37) | 0.76 (0.37, 1.57) | 0.46 |
150–200 | 12 | 53 | 0.58 (0.26, 1.33) | 0.52 (0.21, 1.28) | 0.16 |
≥ 200 | 33 | 176 | 1.14 (0.57, 2.27) | 0.68 (0.32, 1.43) | 0.31 |
History of TB infection | |||||
No | 56 | 273 | 1.0 | 1.0 | |
Yes | 25 | 126 | 0.58 (0.36, 0.94 | 0.74 (0.43, 1.26) | 0.27 |
History of ART regimen change | |||||
No | 54 | 273 | 1.0 | 1.0 | |
Yes | 30 | 127 | 0.72 (0.46, 1.14) | 1.59 (0.9, 2.8) | 0.11 |